Lilly
  • Prescribing Information
  • Patient Prescribing Information
Menu closed
Lilly
  • Prescribing Information
  • Patient Prescribing Information
  • For Patients
    • ALIMTA® (pemetrexed for injection)
    • CYRAMZA® (ramucirumab)
    • ERBITUX® (cetuximab)
    • Jaypirca™ (pirtobrutinib)
    • Retevmo® (selpercatinib)
    • Verzenio Continuous Care™ Support Program
  • For Healthcare Providers
    • Support and Resources
  • Contact Us
Globe Loading... Reveal available languages

Lilly Oncology Support Center Sitemap

For Patients

For Patients Home

  • ALIMTA® (pemetrexed for injection)
  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Jaypirca™ (pirtobrutinib)
  • Retevmo® (selpercatinib)
  • Verzenio Continuous Care™ Support Program

For Healthcare Providers

For Healthcare Providers Home

  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Jaypirca™ (pirtobrutinib)
  • Retevmo® (selpercatinib)
  • Verzenio® (abemaciclib)
  • Support and Resources

Contact Us

Terms of Use
Privacy Statement
Accessibility Statement
Sitemap

To speak to customer support:
Call 1-866-472-8663
Monday - Friday, 8am — 10pm ET

This site is intended for US residents ages 18 and over.

PP-OC-US-0369 01/2023 ©Lilly USA, LLC 2023. All rights reserved.

ALIMTA®, CYRAMZA®, ERBITUX®, Retevmo®, and Verzenio® are registered trademarks and Jaypirca™ and Verzenio Continuous Care™ are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Other product/company names mentioned herein are the property of their respective owners.

Terms of UsePrivacy StatementAccessibility StatementSitemap
Lilly